CoChat

Gender‐related issues in the pharmacology of new anti‐obesity drugs

Cataldi, Mauro, Muscogiuri, Giovanna, Savastano, Silvia, Barrea, Luigi, Guida, Bruna, Taglialatela, Maurizio, Colao, Annamaria · 2019 · Obesity Reviews
Cited by 36

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Summary: Four new medicines—liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate—have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease. To achieve satisfactory anti‐obesity goals, the use of these new medicines should be optimized and tailored to specific patient subpopulations also by applying dose adjustments if needed. In the present review, we posit that gender could be among the factors influencing the activity of the new obesity drugs both because of pharmacokinetic and pharmacodynamic factors. Although evidence from premarketing clinical studies suggested that no dose adjustment by gender is necessary for any of these new medicines, these studies were not specifically designed to identify gender‐related differences. This observation, together with the strong theoretical background supporting the hypothesis of a gender‐dimorphic response, strongly call upon an urgent need of new real‐life data on gender‐related difference in the pharmacology of these new obesity drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/obr.12805

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 36

Metadata

Authors
Cataldi, M., Muscogiuri, G., Savastano, S., Barrea, L., Guida, B., Taglialatela, M., & Colao, A.
Venue
Obesity Reviews
Publisher
Wiley
Published
2018-12-27
Volume
20
Issue
3
Pages
375-384
ISSN
  • 1467-7881 (ISSN-L)
  • 1467-789X
OpenAlex
W2908423447
Cited by
36
References
13
FWCI
2.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.